Medical — Cost of products sold
Becton, Dickinson and Company Medical — Cost of products sold remained flat by 0.0% to $1.37B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 9.0%, from $1.25B to $1.37B. Over 2 years (FY 2023 to FY 2025), Medical — Cost of products sold shows an upward trend with a 7.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase relative to revenue may indicate rising input costs or supply chain inefficiencies, while a decrease suggests improved manufacturing productivity.
Detailed definition
The direct costs associated with manufacturing and distributing the medical products sold within the segment. This inclu...
Peer comparison
Commonly referred to as Cost of Goods Sold (COGS) in standard financial reporting.
bdx_segment_medical_cost_of_products_soldHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $4.72B | $5.02B | $5.46B |
| YoY Change | — | +6.3% | +9.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's medical — cost of products sold?
- Becton, Dickinson and Company (BDX) reported medical — cost of products sold of $1.37B in Q3 2025.
- How has Becton, Dickinson and Company's medical — cost of products sold changed year-over-year?
- Becton, Dickinson and Company's medical — cost of products sold increased by 9.0% year-over-year, from $1.25B to $1.37B.
- What is the long-term trend for Becton, Dickinson and Company's medical — cost of products sold?
- Over 2 years (2023 to 2025), Becton, Dickinson and Company's medical — cost of products sold has grown at a 7.6% compound annual growth rate (CAGR), from $4.72B to $5.46B.
- What does medical — cost of products sold mean?
- Direct costs incurred to manufacture and deliver medical products.